• linkedin
  • Increase Font
  • Sharebar

    Exploring sirolimus as potential alternative therapy for persistent AMD

    Anti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.

    With anti-VEGF therapy, visual acuity deteriorated by more than 2 lines at 5 years after the start of treatment compared with the peak at 2 years. Another challenge is that intraretinal fluid was present in 60% of patients after 5 years, despite treatment, which resulted in worse visual acuity outcomes, he noted.

    In addition, some evidence indicates that monthly injections of anti-VEGF drugs increase the development of geographic atrophy, according to Dr. Maturi, who is in private practice, Midwest Eye Institute, Indianapolis.

    Dr. Maturi suggested there might be a benefit in discovering alternative treatments.

    Sirolimus (also known as rapamycin; DE-109, Santen Pharmaceutical Co.) might be an acceptable alternative, according to Dr. Maturi.

    Central subfield thickness


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';